MedTrace Logo

Irritable Bowel Syndrome (IBS) Treatment With H1-receptor Antagonists

NCT01144832 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2016-01-28

No results posted yet for this study

Summary

Purpose:

To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine.

Design:

Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).

End points:

End point is the effect of treatment on clinical symptoms and visceral hypersensitivity which will be evaluated with a barostat test.

Conditions

  • Irritable Bowel Syndrome

Interventions

DRUG

ebastine

20 milligram capsule once daily

DRUG

placebo capsule

one capsule once daily

Sponsors & Collaborators

  • KU Leuven

    lead OTHER

Principal Investigators

  • Guy Boeckxstaens, M.D. · Catholic University Leuven

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01144832 on ClinicalTrials.gov